Richard Pratley, MD

Richard Pratley, MD

Senior Investigator
Translational Research Institute for Metabolism and Diabetes
Medical Director, Florida Hospital Diabetes Institute (FHDI)
Professor, Sanford-Burnham Medical Research Institute at Lake Nona
Orlando, Florida

Related Videos

What do we know about dosing as it might impact CV outcomes, for liraglutide in the LEADER Trial, and how does this compare to what we learned from SGLT2 inhibitor-based CV outcomes trials? Video

What do we know about dosing as it might impact CV outcomes, for liraglutide in the LEADER Trial, and how does this compare to what we learned from SGLT2 inhibitor-based CV outcomes trials?

What do we know about dosing as it might impact CV outcomes, for liraglutide in the LEADER Trial, and how does this compare to what we learned from SGLT2 inhibitor-based CV outcomes trials?

What are the translational implications of the LEADER trial based on the results reported at ADA 2016? Video

What are the translational implications of the LEADER trial based on the results reported at ADA 2016?

What are the translational implications of the LEADER trial based on the results reported at ADA 2016?

Can you review for us the design and rationale of the LEADER trial? Video

Can you review for us the design and rationale of the LEADER trial?

Can you review for us the design and rationale of the LEADER trial?

How do make sense of the results and designs of the various cardiovascular outcome trials, including the LEADER trial, in patients with T2D and what do you believe is the take home message? Video

How do make sense of the results and designs of the various cardiovascular outcome trials, including the LEADER trial, in patients with T2D and what do you believe is the take home message?

How do make sense of the results and designs of the various cardiovascular outcome trials, including the LEADER trial, in patients with T2D and what do you believe is the take home message?

What are the important developments at ADA 2016 as far as GLP-1 RAs? Video

What are the important developments at ADA 2016 as far as GLP-1 RAs?

What are the important developments at ADA 2016 as far as GLP-1 RAs?

What do we know about dosing as it might impact CV outcomes, for liraglutide in the LEADER Trial, and how does this compare to what we learned from SGLT2 inhibitor-based CV outcomes trials? Video

What do we know about dosing as it might impact CV outcomes, for liraglutide in the LEADER Trial, and how does this compare to what we learned from SGLT2 inhibitor-based CV outcomes trials?

What do we know about dosing as it might impact CV outcomes, for liraglutide in the LEADER Trial, and how does this compare to what we learned from SGLT2 inhibitor-based CV outcomes trials?

What are the translational implications of the LEADER trial based on the results reported at ADA 2016? Video

What are the translational implications of the LEADER trial based on the results reported at ADA 2016?

What are the translational implications of the LEADER trial based on the results reported at ADA 2016?

Can you review for us the design and rationale of the LEADER trial? Video

Can you review for us the design and rationale of the LEADER trial?

Can you review for us the design and rationale of the LEADER trial?

How do make sense of the results and designs of the various cardiovascular outcome trials, including the LEADER trial, in patients with T2D and what do you believe is the take home message? Video

How do make sense of the results and designs of the various cardiovascular outcome trials, including the LEADER trial, in patients with T2D and what do you believe is the take home message?

How do make sense of the results and designs of the various cardiovascular outcome trials, including the LEADER trial, in patients with T2D and what do you believe is the take home message?